search
Back to results

Integration of Hypertension Management Into HIV Care in Nigeria (TASSH NIMR)

Primary Purpose

Human Immunodeficiency Virus, Hypertension

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Task-shifting strategy for HTN control (TASSH) protocol
Sponsored by
NYU Langone Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Human Immunodeficiency Virus focused on measuring Hypertension, Implementation science research, Integrated models, Practice Facilitation, People living with HIV, Human Immunodeficiency Virus, Cluster trial

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Be an adult aged 18 years and older.
  • Attends one of the 30 HIV clinics.
  • Have a diagnosis of HTN with uncontrolled blood pressure, i.e. BP is 140-179/90-100 mm Hg.
  • Ability to provide consent.

Exclusion Criteria:

  • BP>180/100 mm Hg;
  • history of chronic kidney disease, heart disease, diabetes or stroke, pregnancy
  • Inability to provide informed consent.
  • Refusal to participate in the study.

Sites / Locations

  • Saint Louis University (SLU)
  • Nigerian Institute of Medical Research (NIMR)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Self-directed without Practice Facilitation (PF)

With Practice Facilitation (PF)

Arm Description

Participants will be identified from HIV clinics during routine visits and provided standard of care.

Participants will be identified from HIV clinics during routine visits and will receive the task-shifting strategy for HTN control (TASSH) protocol.

Outcomes

Primary Outcome Measures

Change in systolic Blood Pressure
The primary outcome is change in systolic blood pressure (SBP) from baseline to 12 months. Following the research investigators' existing TASSH protocol, the SBP reduction in patients will assessed as mean change in systolic BP from baseline to 12 months. Blood pressure will be taken with valid automated BP device from the existing TASSH protocol.

Secondary Outcome Measures

The rate of adoption of TASSH across participating primary health centers (PHCs) at 12- and 24 months respectively.
Rate of adoption of TASSH is defined as the proportion of patients who were correctly diagnosed with hypertension, received lifestyle counseling and antihypertensive treatment from HIV nurses at 12 months. In order to assess this measure, the nurses will complete a questionnaire inquiring about the number of patients with uncontrolled HTN who received lifestyle counseling and medication treatment. For this purpose, all nurses will be required to keep an attendance log sheet for their patients' visits.
The rate of sustainability of TASSH across participating primary health centers (PHCs) at 12- and 24 months respectively.
Sustainability of TASSH is defined as the maintenance of TASSH uptake at the HIV clinics at 24 months (one year after the end of the intervention). Sustainability will be assessed with a quantitative measure similar to adoption (as defined above) and qualitatively, based on interviews with nurses and clinic leadership at 24 months. For this purpose, two research coordinators will conduct the interviews with two nurses and one key leadership personnel at each primary health center (PHCs). The interviews will be guided by Consolidated Framework for Implementation Research (CFIR) and inquire about attitudes regarding the implementation of TASSH, barriers, facilitators, and implications for scalability.
Change in Implementation Climate of Mediators of TASSH across the primary health centers (PHCs) at 12 and 24 months.
Implementation Climate will be assessed with the Implementation Climate Scale. It measures shared perceptions of policies, practices, procedures, and behaviors that are expected, supported, and rewarded to facilitate effective evidence-based practice (EBP) implementation. It has a Cronbach's alpha of .91. The six subscales of EBP Implementation Climate are: focus on EBP (α=.91), educational support for EBP (α=.84), recognition for EBP (α=.88), rewards for EBP (α=.81), selection for EBP (α=.89), and selection for openness (α=.91).
Change in Implementation Leadership of Mediators of TASSH across the primary health centers (PHCs) at 12 and 24 months.
Implementation Leadership will be assessed with the Implementation Leadership Scale (ILS). It is a 12-item measure with four subscales: Proactive Leadership (α=.95), Knowledgeable Leadership (α=.96), Supportive Leadership (α=.95), and perseverant leadership (α=.96) and a total score (α=.98).
Change in Proficiency of Mediators of TASSH across the primary health centers (PHCs) at 12 and 24 months.
Organizational Culture domain of the Organizational Social Context Scale is a 15-item Proficiency subscale used to evaluate the practice capacity proficiency level of the primary health centers (PHCs). Proficient Organizational Cultures are those characterized by shared norms and expectations that the nurses are skilled service providers, and have current knowledge of the TASSH protocol. Items are completed using a 5-point rating scale ranging from 1 (never) to 5 (always) with measures such as responsiveness (e.g., 'members of my organizational unit are expected to be responsive to the needs of each patient') and competence (e.g., 'members of my organizational unit are expected to have up-to-date knowledge'). Alpha reliability for the proficient culture scale is .89.
Change in Organizational Readiness of Mediators of TASSH across the primary health centers (PHCs) at 12 and 24 months.
Organizational Readiness to Change is assessed with the 12-item Evidence Scale, which evaluates the strength of the evidence for the proposed change/innovation. It will be used to evaluate intervention process measures focused on CFIR's Evidence Strength & Quality and Relative Advantage construct. Each item measures the extent to which a respondent agrees or disagrees with the item statement on a 5-point Likert- type scale (1 = strongly disagree; 5 = strongly agree) and the Cronbach α=0.74.
Change in implementation process across the primary health centers (PHCs) at 12 and 24 months.
External change agent support is a 3-item tool that evaluates support provided by external facilitators, the expectations about performance and improvement, and the ways to achieve the goal of the project. Items are scored on a 5-point Likert scale and the Cronbach α=0.77.
Change in Organizational capacity to change across the primary health centers (PHCs) at 12 and 24 months.
Organizational Readiness to Change (Facilitation Scale-8-items), which evaluates organizational capacity to facilitate change will be used to evaluate implementation process measures focused on CFIR Engaging construct. Each item measures the extent to which a respondent agrees or disagrees with the item statement on a 5-point Likert-type scale (1 = strongly disagree; 5 = strongly agree). It has Cronbach α=0.95.

Full Information

First Posted
January 8, 2021
Last Updated
December 1, 2022
Sponsor
NYU Langone Health
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT04704336
Brief Title
Integration of Hypertension Management Into HIV Care in Nigeria
Acronym
TASSH NIMR
Official Title
Integration of Hypertension Management Into HIV Care in Nigeria: A Task Strengthening Strategy
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 13, 2021 (Actual)
Primary Completion Date
October 31, 2025 (Anticipated)
Study Completion Date
December 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NYU Langone Health
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study evaluates a tailored-practice facilitation (PF) strategy for integrating a task strengthening strategy for hypertension control (TASSH) for the care of patients living with HIV (PWH) within primary health centers (PHCs) in Lagos, Nigeria.
Detailed Description
Although access to antiretroviral therapy has led to increased survival among people living with HIV (PWH) in Africa, this population now has higher cardiovascular disease (CVD) - mortality than the general population largely due to an increased burden of hypertension. In Nigeria, the acute shortage of physicians limits the capacity to control hypertension among PWH at the primary care level where the majority receive treatment. This study proposes the use of practice facilitation (PF) - which will provide external expertise on practice redesign and a tailored approach to delivery of the evidence-based task strengthening strategy - to integrate hypertension into the HIV care model. Using a clinical-effectiveness implementation design, we will evaluate the effect of a PF strategy for integrating an evidence-based intervention for hypertension (HTN) control into HIV care among 960 patients with uncontrolled HTN in 30 primary health centers (PHCs) in Nigeria. Study is in 3 phases: 1) a pre-implementation phase that will develop a tailored PF intervention for integrating TASSH into HIV clinics; 2) an implementation phase that will compare the clinical effectiveness of PF vs. a self-directed condition (receipt of information on TASSH without PF) on BP reduction; and 3) a post- implementation phase to evaluate the effect of PF vs. self-directed condition on the adoption and sustainability of TASSH. The PF intervention comprises: (a) an advisory board to provide leadership support for implementing TASSH in HIV clinics; (b) training of the HIV nurses on TASSH protocol; and (c) training of practice facilitators, who will serve as coaches, provide support, and performance feedback to the HIV nurses

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Human Immunodeficiency Virus, Hypertension
Keywords
Hypertension, Implementation science research, Integrated models, Practice Facilitation, People living with HIV, Human Immunodeficiency Virus, Cluster trial

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
960 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Self-directed without Practice Facilitation (PF)
Arm Type
No Intervention
Arm Description
Participants will be identified from HIV clinics during routine visits and provided standard of care.
Arm Title
With Practice Facilitation (PF)
Arm Type
Experimental
Arm Description
Participants will be identified from HIV clinics during routine visits and will receive the task-shifting strategy for HTN control (TASSH) protocol.
Intervention Type
Behavioral
Intervention Name(s)
Task-shifting strategy for HTN control (TASSH) protocol
Intervention Description
The TASSH protocol include the following 4 steps: 1). Identify HIV patients with uncontrolled HTN: trained HIV nurses will take patients' medical history (whether or not they have a diagnosis of diabetes, heart attack, stroke, heart failure, smoking). 2) Next, they will measure the patients' weight, height, waist circumference and BP with a valid automated device following standard procedures and then conduct lab tests with point-of-care testing on blood glucose, lipids and urine dip stick. 3) Initiate lifestyle counseling and medication treatment every 1-3 months: The nurses will next counsel eligible patients on lifestyle behaviors for 20 to 30 minutes (increased intake of fruits and vegetables, moderate physical activity and reduce salt intake). 4). Refer patients with complicated HTN to physicians for further care
Primary Outcome Measure Information:
Title
Change in systolic Blood Pressure
Description
The primary outcome is change in systolic blood pressure (SBP) from baseline to 12 months. Following the research investigators' existing TASSH protocol, the SBP reduction in patients will assessed as mean change in systolic BP from baseline to 12 months. Blood pressure will be taken with valid automated BP device from the existing TASSH protocol.
Time Frame
baseline, 6 months, 12 months, 18 months and 24 months
Secondary Outcome Measure Information:
Title
The rate of adoption of TASSH across participating primary health centers (PHCs) at 12- and 24 months respectively.
Description
Rate of adoption of TASSH is defined as the proportion of patients who were correctly diagnosed with hypertension, received lifestyle counseling and antihypertensive treatment from HIV nurses at 12 months. In order to assess this measure, the nurses will complete a questionnaire inquiring about the number of patients with uncontrolled HTN who received lifestyle counseling and medication treatment. For this purpose, all nurses will be required to keep an attendance log sheet for their patients' visits.
Time Frame
12 months
Title
The rate of sustainability of TASSH across participating primary health centers (PHCs) at 12- and 24 months respectively.
Description
Sustainability of TASSH is defined as the maintenance of TASSH uptake at the HIV clinics at 24 months (one year after the end of the intervention). Sustainability will be assessed with a quantitative measure similar to adoption (as defined above) and qualitatively, based on interviews with nurses and clinic leadership at 24 months. For this purpose, two research coordinators will conduct the interviews with two nurses and one key leadership personnel at each primary health center (PHCs). The interviews will be guided by Consolidated Framework for Implementation Research (CFIR) and inquire about attitudes regarding the implementation of TASSH, barriers, facilitators, and implications for scalability.
Time Frame
24 months
Title
Change in Implementation Climate of Mediators of TASSH across the primary health centers (PHCs) at 12 and 24 months.
Description
Implementation Climate will be assessed with the Implementation Climate Scale. It measures shared perceptions of policies, practices, procedures, and behaviors that are expected, supported, and rewarded to facilitate effective evidence-based practice (EBP) implementation. It has a Cronbach's alpha of .91. The six subscales of EBP Implementation Climate are: focus on EBP (α=.91), educational support for EBP (α=.84), recognition for EBP (α=.88), rewards for EBP (α=.81), selection for EBP (α=.89), and selection for openness (α=.91).
Time Frame
12 months and 24 months
Title
Change in Implementation Leadership of Mediators of TASSH across the primary health centers (PHCs) at 12 and 24 months.
Description
Implementation Leadership will be assessed with the Implementation Leadership Scale (ILS). It is a 12-item measure with four subscales: Proactive Leadership (α=.95), Knowledgeable Leadership (α=.96), Supportive Leadership (α=.95), and perseverant leadership (α=.96) and a total score (α=.98).
Time Frame
12 months and 24 months
Title
Change in Proficiency of Mediators of TASSH across the primary health centers (PHCs) at 12 and 24 months.
Description
Organizational Culture domain of the Organizational Social Context Scale is a 15-item Proficiency subscale used to evaluate the practice capacity proficiency level of the primary health centers (PHCs). Proficient Organizational Cultures are those characterized by shared norms and expectations that the nurses are skilled service providers, and have current knowledge of the TASSH protocol. Items are completed using a 5-point rating scale ranging from 1 (never) to 5 (always) with measures such as responsiveness (e.g., 'members of my organizational unit are expected to be responsive to the needs of each patient') and competence (e.g., 'members of my organizational unit are expected to have up-to-date knowledge'). Alpha reliability for the proficient culture scale is .89.
Time Frame
12 months and 24 months
Title
Change in Organizational Readiness of Mediators of TASSH across the primary health centers (PHCs) at 12 and 24 months.
Description
Organizational Readiness to Change is assessed with the 12-item Evidence Scale, which evaluates the strength of the evidence for the proposed change/innovation. It will be used to evaluate intervention process measures focused on CFIR's Evidence Strength & Quality and Relative Advantage construct. Each item measures the extent to which a respondent agrees or disagrees with the item statement on a 5-point Likert- type scale (1 = strongly disagree; 5 = strongly agree) and the Cronbach α=0.74.
Time Frame
12 months and 24 months
Title
Change in implementation process across the primary health centers (PHCs) at 12 and 24 months.
Description
External change agent support is a 3-item tool that evaluates support provided by external facilitators, the expectations about performance and improvement, and the ways to achieve the goal of the project. Items are scored on a 5-point Likert scale and the Cronbach α=0.77.
Time Frame
12 months and 24 months
Title
Change in Organizational capacity to change across the primary health centers (PHCs) at 12 and 24 months.
Description
Organizational Readiness to Change (Facilitation Scale-8-items), which evaluates organizational capacity to facilitate change will be used to evaluate implementation process measures focused on CFIR Engaging construct. Each item measures the extent to which a respondent agrees or disagrees with the item statement on a 5-point Likert-type scale (1 = strongly disagree; 5 = strongly agree). It has Cronbach α=0.95.
Time Frame
12 months and 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Be an adult aged 18 years and older. Attends one of the 30 HIV clinics. Have a diagnosis of HTN with uncontrolled blood pressure, i.e. BP is 140-179/90-100 mm Hg. Ability to provide consent. Exclusion Criteria: BP>180/100 mm Hg; history of chronic kidney disease, heart disease, diabetes or stroke, pregnancy Inability to provide informed consent. Refusal to participate in the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Olugbenga Ogedegbe, MD
Phone
646-501-3435
Email
Olugbenga.Ogedegbe@nyulangone.org
First Name & Middle Initial & Last Name or Official Title & Degree
Lloyd Gyamfi
Phone
646-501-3469
Email
Lloyd.Gyamfi@nyulangone.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Olugbenga Ogedegbe, MD
Organizational Affiliation
NYU Langone Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
Saint Louis University (SLU)
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63103
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Juliet Iwelunmor, PhD
Email
juliet.iwelunmor@slu.edu
First Name & Middle Initial & Last Name & Degree
David A Oladele, MB,BS, MPH, MSc
Email
David.Oladele@slu.edu
First Name & Middle Initial & Last Name & Degree
Juliet Iwelunmor, PhD
Facility Name
Nigerian Institute of Medical Research (NIMR)
City
Yaba
State/Province
Lagos
Country
Nigeria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Oliver C Ezechi, MBBS, MPA, PhD, FWACS, FMCOG
Phone
+2348033065683
Email
oezechi@yahoo.co.uk
First Name & Middle Initial & Last Name & Degree
Tosin Odubela, MD, MPH
Phone
+2348083946078
Email
amco4all@yahoo.com
First Name & Middle Initial & Last Name & Degree
Oliver C Ezechi, MBBS, MPA, PhD, FWACS, FMCOG

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
All of the individual participant data collected during the trial, after deidentification.
IPD Sharing Time Frame
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD Sharing Access Criteria
The investigator who proposed to use the data.To achieve aims in the approved proposal. For individual participant data meta-analysis. Requests should be directed to Olugbenga.Ogedegbe@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
Citations:
PubMed Identifier
35428342
Citation
Iwelunmor J, Ezechi O, Obiezu-Umeh C, Oladele D, Nwaozuru U, Aifah A, Gyamfi J, Gbajabiamila T, Musa AZ, Onakomaiya D, Rakhra A, Jiyuan H, Odubela O, Idigbe I, Engelhart A, Tayo BO, Ogedegbe G. Factors influencing the integration of evidence-based task-strengthening strategies for hypertension control within HIV clinics in Nigeria. Implement Sci Commun. 2022 Apr 15;3(1):43. doi: 10.1186/s43058-022-00289-z.
Results Reference
derived
PubMed Identifier
34789277
Citation
Aifah AA, Odubela O, Rakhra A, Onakomaiya D, Hu J, Nwaozuru U, Oladele DA, Odusola AO, Idigbe I, Musa AZ, Akere A, Tayo B, Ogedegbe G, Iwelunmor J, Ezechi O. Integration of a task strengthening strategy for hypertension management into HIV care in Nigeria: a cluster randomized controlled trial study protocol. Implement Sci. 2021 Nov 16;16(1):96. doi: 10.1186/s13012-021-01167-3.
Results Reference
derived

Learn more about this trial

Integration of Hypertension Management Into HIV Care in Nigeria

We'll reach out to this number within 24 hrs